Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jie Jin, Rumiko Okamoto, Sung-Soo Yoon, Lee-Yung Shih, Jun Zhu, Ting Liu, Xiaonan Hong, Lixia Pei, Brendan Rooney, Helgi van de Velde & Huiqiang Huang. (2018) Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma. OncoTargets and Therapy 11, pages 3869-3882.
Read now
Read now
Danyu Sun & Mitchell R Smith. (2014) Bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Orphan Drugs 2:11, pages 1233-1241.
Read now
Read now
Andre Goy. (2013) Mantle cell lymphoma: continuously improving the odds!. Expert Opinion on Orphan Drugs 1:12, pages 1001-1018.
Read now
Read now
Articles from other publishers (26)
Noa Biran,Pooja Phull,andand & Andre Goy. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies
331
360
.
Jie Wang & Ting Liu. (2022) NF-κB Signaling Pathway and Efficacy of Bortezomib-Based Combination Chemotherapy in Patients with Non-Hodgkin's Lymphoma. International Journal of Pharmacology 18:5, pages 850-855.
Crossref
Crossref
Stefano Fogli, Sara Galimberti, Veronica Gori, Marzia Del Re & Romano Danesi. (2021) Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacological Research 167, pages 105537.
Crossref
Crossref
Yucai Wang, Thomas M. Habermann, Sophia S. Wang, Matthew J. Maurer, Vivekananda Sarangi, Brian K. Link, Andrew L. Feldman, David J. Inwards, Thomas E. Witzig, Wendy Cozen, Nathaniel Rothman, Yan Asmann, Susan L. Slager & James R. Cerhan. (2019) Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. American Journal of Hematology 94:6.
Crossref
Crossref
Yun Liu, Wen-Jing Huang, Min-Ting Lin, Jia-Jun Li & Jian-Ye Zhang. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
207
228
.
John P. LeonardKathryn S. KolibabaJames A. ReevesAnil TulpuleIan W. FlinnTatjana KolevskaRobert RoblesChristopher R. FlowersRobert CollinsNicholas J. DiBellaSteven W. PapishParameswaran VenugopalAndrew HorodnerAmir TabatabaiJulio HajdenbergJaehong ParkRachel NeuwirthGeorge MulliganKaveri SuryanarayanDixie-Lee EsseltineSven de Vos. (2017) Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology 35:31, pages 3538-3546.
Crossref
Crossref
Gergely Varga, Gábor Mikala, Katalin Piroska Kiss, Éva Kosóczki, Edit Szabó, Nóra Meggyesi, Katalin Balassa, Petra Kövy, Bálint Tegze, Gergely Szombath, Attila Tordai, Hajnalka Andrikovics, László Homolya & Tamás Masszi. (2017) Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 17:11, pages 734-742.
Crossref
Crossref
Jia Ruan & Peter Martin. (2016) Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. Current Hematologic Malignancy Reports 11:3, pages 234-240.
Crossref
Crossref
Brian G. Till, Hongli Li, Steven H. Bernstein, Richard I. Fisher, W. Richard Burack, Lisa M. Rimsza, Justin D. Floyd, Marco A. DaSilva, Dennis F. MooreJrJr, Olga Pozdnyakova, Sonali M. Smith, Michael LeBlanc & Jonathan W. Friedberg. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. British Journal of Haematology 172:2, pages 208-218.
Crossref
Crossref
Michael L Wang, Hun Lee, Hubert Chuang, Nicolaus Wagner-Bartak, Frederick Hagemeister, Jason Westin, Luis Fayad, Felipe Samaniego, Francesco Turturro, Yasuhiro Oki, Wendy Chen, Maria Badillo, Krystle Nomie, Maria DeLa Rosa, Donglu Zhao, Laura Lam, Alicia Addison, Hui Zhang, Ken H Young, Shaoying Li, David Santos, L Jeffrey Medeiros, Richard Champlin, Jorge Romaguera & Leo Zhang. (2016) Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. The Lancet Oncology 17:1, pages 48-56.
Crossref
Crossref
Sonali M. Smith & Julie M. Vose. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
169
176
.
Tadeusz Robak. (2015) Bortezomib in the treatment of mantle cell lymphoma. Future Oncology 11:20, pages 2807-2818.
Crossref
Crossref
Andre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, Michael J. Robertson, Irit Avivi, Jacob M. Rowe, Raoul Herbrecht, Achiel Van Hoof, Lei Zhang, Sherri Cicero, Tommy Fu & Thomas Witzig. (2015) Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial. British Journal of Haematology 170:4, pages 496-503.
Crossref
Crossref
Tadeusz Robak, Huiqiang Huang, Jie Jin, Jun Zhu, Ting Liu, Olga Samoilova, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Evgenii Osmanov, Julia Alexeeva, Juliana Pereira, Johannes Drach, Jiri Mayer, Xiaonan Hong, Rumiko Okamoto, Lixia Pei, Brendan Rooney, Helgi van de Velde & Franco Cavalli. (2015) Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. New England Journal of Medicine 372:10, pages 944-953.
Crossref
Crossref
Yujie Zhao, Nathan R. Foster, Jeffrey P. Meyers, Sachdev P. Thomas, Donald W. Northfelt, Kendrith M. RowlandJrJr, Bassam I. Mattar, David B. Johnson, Julian R. Molina, Sumithra J. Mandrekar, Steven E. Schild, James D. BeardenIIIIII, Marie-Christine Aubry & Alex A. Adjei. (2015) A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non?Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of Thoracic Oncology 10:1, pages 172-180.
Crossref
Crossref
Owen A. O’Connor, Jennifer Amengual, Changchun Deng, Ahmed Sawas, Bachir Alobeid, Daniela Hoehn & Govind Bhagat. 2015. The Molecular Basis of Cancer. The Molecular Basis of Cancer
433
454.e3
.
Xin He, Zhigang Chen, Tao Fu, Xueli Jin, Teng Yu, Yun Liang, Xiaoying Zhao & Liansheng Huang. (2014) Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer 14:1.
Crossref
Crossref
Holly A.F. Stessman, Linda B. Baughn, Aaron Sarver, Tian Xia, Raamesh Deshpande, Aatif Mansoor, Susan A. Walsh, John J. Sunderland, Nathan G. Dolloff, Michael A. Linden, Fenghuang Zhan, Siegfried Janz, Chad L. Myers & Brian G. Van Ness. (2013) Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model. Molecular Cancer Therapeutics 12:6, pages 1140-1150.
Crossref
Crossref
Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yusri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan & Deborah Ricci. (2013) Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab. Clinical Cancer Research 19:9, pages 2551-2561.
Crossref
Crossref
John Gerecitano, Sivaraman Gounder, Julie Teruya-Feldstein, Maria Arcila, Shahiba Ogilvie, Camille Gonzalez, Dorothy Lin, Junting Zheng, Zhigang Zhang, Alice McDonald, George Mulligan & Owen A. O'Connor. (2012) Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma. British Journal of Haematology 158:2, pages 290-292.
Crossref
Crossref
Dixie-Lee Esseltine & George Mulligan. (2012) An Historic Perspective of Proteasome Inhibition. Seminars in Hematology 49:3, pages 196-206.
Crossref
Crossref
Anthony R. Mato, Tatyana Feldman & André Goy. (2012) Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside. The Oncologist 17:5, pages 694-707.
Crossref
Crossref
Boris Cvek. 2012. The Proteasomal System in Aging and Disease. The Proteasomal System in Aging and Disease
161
226
.
Julie E. Chang & Brad S. Kahl. (2011) Current Status of Targeted Therapies for Mantle Cell Lymphoma. Drugs 71:17, pages 2307-2326.
Crossref
Crossref
Jonathan W. Friedberg. (2011) New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice. Clinical Cancer Research 17:19, pages 6112-6117.
Crossref
Crossref
Nathan FowlerBrad S. KahlPeter LeeJeffrey V. MatousAmanda F. CashenSamuel A. JacobsJeffrey LetzerBipinkumar AminMichael E. WilliamsSonali SmithAlfred SalehPeter RosenHongliang ShiSudha ParasuramanBruce D. Cheson. (2011) Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. Journal of Clinical Oncology 29:25, pages 3389-3395.
Crossref
Crossref